CG Oncology (CGON) Accumulated Expenses (2023 - 2026)
CG Oncology's (CGON) quarterly Accumulated Expenses came in at $25.9 million in Q1 2026, up 65.52% YoY from $15.7 million in Q1 2025, and up 7.05% on a QoQ basis from $24.2 million in Q4 2025.
CG Oncology (CGON) Accumulated Expenses (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Accumulated Expenses data on file, last reported at $25.9 million in Q1 2026.
- Quarterly Accumulated Expenses rose 65.52% year-over-year to $25.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.9 million (up 65.52% YoY) and the FY2025 annual result came in at $24.2 million, up 65.07% from the prior year.
- Accumulated Expenses advanced to $25.9 million in Q1 2026, from $24.2 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $25.9 million in Q1 2026 to a low of $5.1 million in Q1 2024.
- A 4-year average of $15.8 million and a median of $15.2 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Accumulated Expenses surged 40.43% — and 2025, when it jumped 222.36%.
- Tracing CGON's Accumulated Expenses over 4 years: stood at $10.4 million in 2023, then surged by 40.43% to $14.7 million in 2024, then jumped by 65.07% to $24.2 million in 2025, then advanced by 7.05% to $25.9 million in 2026.
- The last three Accumulated Expenses figures came in at $25.9 million (Q1 2026), $24.2 million (Q4 2025), and $20.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.53 Mn |
| Mar 31, 2026 | 25.91 Mn |
| Dec 31, 2025 | 24.21 Mn |
| Sep 30, 2025 | 20.42 Mn |
| Jun 30, 2025 | 22.97 Mn |
| Mar 31, 2025 | 15.66 Mn |
| Dec 31, 2024 | 14.67 Mn |
| Sep 30, 2024 | 11.33 Mn |
| Jun 30, 2024 | 7.13 Mn |
| Mar 31, 2024 | 5.11 Mn |
| Dec 31, 2023 | 10.44 Mn |